- Home
- TARA vs KRON Comparison
TARA vs KRON Comparison
Compare TARA & KRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TARA
- KRON
- Stock Information
- Founded
- TARA N/A
- KRON 2017
- Country
- TARA United States
- KRON United States
- Employees
- TARA N/A
- KRON N/A
- Industry
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- KRON Medicinal Chemicals and Botanical Products
- Sector
- TARA Health Care
- KRON Health Care
- Exchange
- TARA Nasdaq
- KRON Nasdaq
- Market Cap
- TARA 52.4M
- KRON 60.3M
- IPO Year
- TARA N/A
- KRON 2020
- Fundamental
- Price
- TARA $5.30
- KRON $0.96
- Analyst Decision
- TARA Strong Buy
- KRON Buy
- Analyst Count
- TARA 3
- KRON 3
- Target Price
- TARA $22.67
- KRON $1.63
- AVG Volume (30 Days)
- TARA 6.6M
- KRON 384.9K
- Earning Date
- TARA 11-12-2024
- KRON 11-13-2024
- Dividend Yield
- TARA N/A
- KRON N/A
- EPS Growth
- TARA N/A
- KRON N/A
- EPS
- TARA N/A
- KRON N/A
- Revenue
- TARA N/A
- KRON $9,864,000.00
- Revenue This Year
- TARA N/A
- KRON $62.21
- Revenue Next Year
- TARA N/A
- KRON N/A
- P/E Ratio
- TARA N/A
- KRON N/A
- Revenue Growth
- TARA N/A
- KRON 146.48
- 52 Week Low
- TARA $1.60
- KRON $0.69
- 52 Week High
- TARA $10.48
- KRON $1.60
- Technical
- Relative Strength Index (RSI)
- TARA 63.59
- KRON 52.82
- Support Level
- TARA $5.27
- KRON $0.92
- Resistance Level
- TARA $6.39
- KRON $1.03
- Average True Range (ATR)
- TARA 0.89
- KRON 0.06
- MACD
- TARA 0.05
- KRON -0.00
- Stochastic Oscillator
- TARA 36.25
- KRON 44.16
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.